The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The sub-advisor’s investment process is designed to highlight stocks of health sciences-related companies.

The investment team considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or lif More

The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.

The sub-advisor’s investment process is designed to highlight stocks of health sciences-related companies.

The investment team considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences.

The fund seeks to capitalize on the rapid growth in global healthcare spending due to impact from COVID-19, coupled with an aging society.

Next, the research team prefers companies demonstrating above-average growth and superior capital appreciation potential.

The team also considers companies exhibiting substantial capacity for growth in revenue through either an expanding market or market share; balance sheet strength; and superior management.

In addition; the team also looks for companies with a dedication to research and product development; and differentiated or superior products and services or a consistent flow of new products and services.

Then the manager constructs a diversified portfolio from a list of companies in the benchmark index favored by the research team and allocates capital based on its conviction level.

Stock selection and portfolio construction is driven by high conviction growth, quality, valuation, and ESG risk criteria.

The portfolio holds 45 to 75 high-quality healthcare companies, addressing themes such as innovative biotechnology and pharmacological treatments, cost-effective medical solutions, preventative health care, and healthy lifestyles.

The fund may invest in U.S. and non-U.S. companies, and may invest up to 15% of its net assets in emerging market securities but no more than 10% in any one emerging market country.

The fund may invest in securities issued in initial public offerings.